Multisystem Cell Therapy for Improvement of Urinary Continence

Inclusion Criteria: Adult women 20y-60y * Incontinence \>/= grade I since at least 6 months * Predominant clinical diagnosis of SUI * Candidate for a surgical treatment (artificial urinary sphincter, synthetic compressive tapes or adjustable balloons). * Post void residual volume of \<100 ml (exclusion of overflow incontinence) * Can independently use toilet without difficulty * Capacity to answer the questionnaires of evaluation * Negative blood test for: Human immunodeficiency virus (HIV 1/2), Hepatitis B HBsAg, Anti HBc, Hepatitis C Anti-HCV-Ab, Syphilis * Competent to comprehend, sign and date informed consent form before any study-specific procedure is performed Exclusion Criteria: * History of anti-incontinence or prolapse surgery. * Previous diagnosis of any of the following conditions, disorders, or diseases of the urinary tract: * Clinically significant cystocele or rectocele * Ureteric bladder, urethral or rectal fistula * Uncorrected congenital abnormality leading to urinary incontinence * Interstitial cystitis * Urinary urgency that results in leakage (as a predominant symptom) * Adult enuresis * Urodynamically proven detrusor instability * Sensory urgency defined as first sensation of bladder fill (urge to void) of \<100 ml; bladder capacity of \<300 ml * No sensation at any time during the simple filling cystometry procedure * Known urethral stenosis (ureterocystoscopy) or urethral diverticulum * History of urogenital cancer or history of pelvic radiotherapy * Women who are pregnant, breast feeding or \<12 months postpartum Note: Female subjects who are surgically sterilized, hysterectomized or post-menopausal for longer than 2 years are not considered as having child bearing potential. No pregnancy test will be performed for this population. * Untreated symptomatic urinary tract infection * Fever (as defined by ≥ 38,5°C, axillar measurement), any infectious disease, cold or flu within the last 7 days * Unstable severe systemic disease including uncontrolled hypertension, unstable angina, or myocardial infarction, severe coagulation disorders, bleeding diathesis, emboli, thrombophlebitis, infectious diseases, poor wound healing, and poorly controlled diabetes mellitus within 6 months before enrolment * Any organic or psychiatric disorder that, in the opinion of the investigator, might prevent the subject from completing the study or interfere with the interpretation of the study results. * Known allergy or intolerance of at least one of the active ingredients or excipients of the investigational products * Known allergy or intolerance of Penicillin or Streptomycin * Known genetically determined or acquired muscular disease. * Known Neurological disorder (Parkinson's disease, multiple sclerosis, spina bifida, medullary traumatism). * Medication regimen including estrogens, anti-estrogens or diuretics where dose and/or frequency has not been stable for at least the past 12 weeks or is anticipated to change during the course of the study. * Chronic use of any of the following drugs and not stopped for at least 2 weeks prior to inclusion into the study: selective serotonin and norepinephrine reuptake inhibitor antidepressant (SSNRI), alpha-receptor antagonists/agonists, beta-3-receptor agonists or anticholinergic/-muscarinic drugs. * Chronic use of any of the following drugs and not stopped for at least 6 months prior to inclusion into the study: Antidepressants or neuroleptic drugs.